Long-term comparative pharmacovigilance of orally transmitted Chagas disease: first report

References

• World Health Organization. Chagas disease in Latin America: an epidemiological update based on 2010 estimates Trypanosoma cruzi infection, transmission and disease. Weekly Epidemiological Record (W.E.R.). 2015;90(6):33–44.
   PubMedGoogle Scholar
• Coura JR. The main sceneries of Chagas disease transmission. The vectors, blood and oral transmission –a comprehensive review. Mem Inst Oswaldo Cruz. 2015;110(3):277–282.
   PubMed Web of Science ®Google Scholar
• Pinto-Dias JCP. Notas sobre o Trypanosoma cruzi e suas características bio-ecológicas, como agente de enfermidades transmitidas por alimentos. Rev Soc Med Trop. 2006;39(4):370–375.
   PubMed Web of Science ®Google Scholar
• Valente SAS, Valente VC, Fraiha Neto H. Transmissão da doença de Chagas: como estamos? Considerações sobre a epidemiologia e transmissão da doença de Chagas na Amazônia Brasileira. Rev Soc Med Trop. 1999;25(Supl. 2):51–55.
   Google Scholar
• Alarcón de Noya B, Noya O. An ecological overview on the factors that drives to Trypanosoma cruzi oral transmission. Acta Trop. 2015;151:94–102.
   PubMed Web of Science ®Google Scholar
• Urbina JA. Parasitological cure of Chagas disease: is it possible? Is it relevant? Mem Inst Oswaldo Cruz. 1999;94(Suppl. I):349–355.
   PubMed Web of Science ®Google Scholar
• Apt BW, Zulantay AI. Estado actual en el tratamiento de la enfermedad de Chagas. Rev Méd Chile. 2011;139(2):247–257.
   PubMedGoogle Scholar
• Bern C. Antitrypanosomal therapy for chronic Chagas’ disease. N Engl J Med. 2011;364(June 30):2527–2534.
   PubMedGoogle Scholar
• Cançado JR. Criteria of Chagas disease cure. Mem Inst Oswaldo Cruz. 1999;94(Suppl. I):331–335.
   PubMed Web of Science ®Google Scholar
• Andrade ALS, Zicker F, Oliveira RM, et al. Randomized trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348(9039):1407–1413.
   PubMed Web of Science ®Google Scholar
• Coura JR, Borges-Pereira J. Chronic phase of Chagas disease: why should it be treated? A comprehensive review. Mem Inst Oswaldo Cruz. 2011;106(6):641–645.
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Segura EL. Treatment of Trypanosoma cruzi infection in the indeterminate phase. experience and current guidelines of treatment in Argentina. Mem Inst Oswaldo Cruz. 1999;94(Suppl. I):363–365.
   PubMed Web of Science ®Google Scholar
• Urbina JA. Recent clinical trials for the etiological treatment of chronic Chagas disease: advances, challenges and perspectives. J Eukaryot Microbiol. 2015;62(1):149–156.
   PubMed Web of Science ®Google Scholar
• Viotti R, Alarcón de Noya B, Araujo-Jorge T, et al. Towards a paradigm shift in the treatment of chronic Chagas disease. Antimicrob Agents Chemother. 2014;58(2):635–639.
   PubMed Web of Science ®Google Scholar
• Andrade SG, Rassi A, Magalhaes JB, et al. Specific chemotherapy of Chagas’ disease: a comparison between the response in patients and experimental animals infected with the same strains. Trans R Soc Trop Med Hyg. 1992;86(6):624–626.
   PubMed Web of Science ®Google Scholar
• Coura JR, Castro SL. A critical review of Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 2002;97(1):3–24.
   PubMed Web of Science ®Google Scholar
• Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol. 2003;19(11):495–501.
   PubMed Web of Science ®Google Scholar
• Ache A, Matos AJ. Interrupting Chagas disease transmission in Venezuela. Rev Inst Med Trop São Paulo. 2001;433(1):37–43.
   Google Scholar
• Feliciangeli MD, Campbell-Lendrum D, Martínez C, et al. Chagas disease control in Venezuela: lessons for the Andean region and beyond. Trends Parasitol. 2003;19(1):44–49.
   PubMed Web of Science ®Google Scholar
• Alarcón de Noya B, Díaz-Bello Z, Colmenares C, et al. Transmisión urbana de la enfermedad de Chagas en Caracas, Venezuela: aspectos epidemiológicos, clínicos y de laboratorio. Biomédica. 2009;20(3):158–164.
   Google Scholar
• Añez N, Crisante G, Parada H. Nuevos casos agudos de enfermedad de Chagas en el occidente de Venezuela. Salus. 2007;11(1):87–90.
   Google Scholar
• Losada M, Burdeinick I, Scharifker D. Miocarditis chagásica aguda fatal en lactante de 9 meses de edad del área urbana. Clin Med HCC. 2000;5(1):45–50.
   Google Scholar
• Morocoima A, Tineo E, Ferrer E, et al. Enfermedad de Chagas en el estado Anzoátegui, Venezuela: registro de un caso agudo y caracterización parasitológica y molecular del aislado. Bol. Mal. Salud Amb. 2008;48(2):121–126.
   Google Scholar
• Alarcón de Noya B, Díaz-Bello Z, Colmenares C, et al. Update on oral Chagas disease outbreaks in Venezuela: epidemiological, clinical and diagnostic approaches. Mem Inst Oswaldo Cruz. 2015;110(3):377–386.
   PubMedGoogle Scholar
• Añez N, Crisante G, Rojas A, et al. A new acute oral Chagas disease outbreak in Mérida, Venezuela: a comprehensive study. Int J Clin Med Res. 2016;3(1):29–37.
   Google Scholar
• Alarcón de Noya B, Díaz-Bello Z, Colmenares C, et al. Large urban outbreak of orally-acquired acute Chagas disease, at a school in Caracas, Venezuela. J Infect Dis. 2010;201(9):1308–1315.
   PubMed Web of Science ®Google Scholar
• Alarcón de Noya B, Díaz-Bello Z, Colmenares C, et al. The performance of laboratory tests in the management of a large outbreak of orally transmitted Chagas disease. Mem Inst Oswaldo Cruz. 2012;107(7):893–898.
   PubMed Web of Science ®Google Scholar
• Amato Neto V. Etiological treatment for infection by Trypanosoma cruzi. Mem Inst Oswaldo Cruz. 1999;94(Suppl. I):337–339.
   PubMedGoogle Scholar
• Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Published: May 28, 2009 v4.03. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. cited: June 14, 2010 Available from: http://www.eortc.be/services/doc/ctc/ctcaev3.pdf.
   Google Scholar
• Secretaria de Vigilância em Saúde do Ministério da Saúde. Consenso Brasileiro em Doença de Chagas. Rev Soc Med Trop. 2005;38(Supl III):29.
   PubMedGoogle Scholar
• Apt BW, Heitmann GI, Jercic LMI, et al. Guías clínicas de la enfermedad de Chagas 2006: parte VI. tratamiento antiparasitario de la enfermedad de Chagas. Rev Chil Infectol. 2008;25(5):384–389.
   PubMedGoogle Scholar
• Coura JR, Abreu LL, Willcox HPF, et al. Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissão interrompida. I. Avaliação preliminar. Rev Soc Med Trop. 1997;30(2):5.
   Google Scholar
• Alarcón de Noya B, Torres J, Suárez JA, et al. Guía para el diagnóstico, manejo y tratamiento de la enfermedad de Chagas en fase aguda a nivel de los establecimientos de salud. Avances Cardiol. 2008;24(4):250–267.
   Google Scholar
• Bianchi F, Cucunubá Z, Guhl F, et al. Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia. Plos Negl Trop Dis. 2015;9(2):e0003465. DOI:10.1371/journal.pntd.0003465
   Google Scholar
• Murcia L, Carrilero B, Albajar Viñas P, et al. Nifurtimox chemotherapy: colateral effects in treated Trypanosoma cruzi infected patients. Rev Esp Quimioter. 2012;25(1):74–75.
   PubMed Web of Science ®Google Scholar
• Schenone HF, Contreras LM, Solari IA, et al. Tratamiento con nifurtimox de la infección chagásica crónica en niños. Rev Méd Chile. 2003;131(9):1089–1090.
   PubMed Web of Science ®Google Scholar
• Altcheh J, Moscatelli G, Moroni S, et al. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics. 2011;127(1):e212–218.
   PubMed Web of Science ®Google Scholar
• Bern C. Chagas disease. N Engl J Med. 2015;373(July 30):456–466.
   PubMedGoogle Scholar
• Forsyth CJ, Hernández S, Olmedo W, et al. Safety profile of nifurtimox for treatment of Chagas disease in the United States. Clin Infect Dis. 2016;63:1056–1062.
   PubMed Web of Science ®Google Scholar
• Castro JA, Montalto de Mecca M, Bartel L. Toxic side effects of drugs used to treat Chagas’ disease (American trypanosomiasis). Hum Exp Toxicol. 2006;25(8):471–479.
   PubMed Web of Science ®Google Scholar
• Sosa-Estani S, Cura E, Velásquez E, et al. Etiological treatment of young woman infected with Trypanosma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop. 2009;42(5):484–487.
   PubMed Web of Science ®Google Scholar
• Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. Plos Negl Trop Dis. 2014;8:e3312.
   PubMed Web of Science ®Google Scholar